OVAGEN INTERNATIONAL LIMITED

Ovagen International Limited is an Irish biotechnology company pioneering a proprietary, commercial‑scale process for producing germ‑free chicken eggs and birds. By eliminating bacterial and viral contaminants at the source, Ovagen supplies a biosecure, flexible and cost‑effective platform that underpins the manufacture of human and animal vaccines, therapeutic proteins and other pharmaceutical products.

The company’s germ‑free eggs deliver zero‑contamination risk and markedly higher viral yields – studies have demonstrated more than 7,000 doses of yellow‑fever virus per egg – translating into substantial cost savings, uninterrupted supply chains and superior vaccine quality. These advantages are especially critical as the world confronts COVID‑19 and prepares for future pandemics, where reliable, high‑volume vaccine production is essential.

Headquartered in Ballina, County Mayo, Ovagen has attracted significant investment, including a €2 million Series A round led by the Western Development Commission, and was awarded the European Innovation Council Seal of Excellence in 2020. With combined decades of life‑sciences R&D